You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 265 No. 22, June 12, 1991 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Special Communication
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Isoniazid as Preventive Therapy in HIV-Infected Intravenous Drug Abusers

A Decision Analysis

Theresa J. Jordan, PhD; Eugene M. Lewit, PhD; Richard L. Montgomery, DDS, MPH; Lee B. Reichman, MD, MPH

JAMA. 1991;265(22):2987-2991.


Abstract

Tuberculin skin testing is a notoriously poor marker of tuberculosis infection in patients who are serologically positive for the human immunodeficiency virus. A decision analysis was performed to determine if and when isoniazid should be prescribed to prevent tuberculosis in these patients. The decision was analyzed for an intravenous drug abuser who may have been anergic, while tuberculin test status, race, and gender were varied. The assumptions and parameter estimates selected for this investigation represent a highly conservative vantage point opposing the use of isoniazid as a preventive therapy. Nevertheless, results showed a benefit from the use of isoniazid as a preventive therapy for all groups, even without tuberculin testing, except tuberculin-negative black women. This benefit of isoniazid therapy increased patient life expectancy as much as 285 days. Further, the decisions continue to favor prescribing isoniazid even when the suspected incidence of tuberculosis infection falls as low as 3% to 8%. Tuberculin testing appears important primarily for black women, since those who have negative tuberculin skin tests may not be candidates for isoniazid therapy.

(JAMA. 1991;265:2987-2991)



Author Affiliations

From the Division of Informatics (Drs Jordan and Montgomery), Department of Medicine (Dr Lewit), and Division of Pulmonary Medicine (Dr Reichman), University of Medicine & Dentistry of New Jersey, New Jersey Medical School, Newark. Dr Lewit is currently affiliated with the David and Lucile Packard Foundation, The Center for the Future of Children, Los Altos, Calif.


Footnotes

Reprint requests to Division of Pulmonary Medicine, University of Medicine & Dentistry of New Jersey, New Jersey Medical School, 150 Bergen St, I-354, Newark, NJ 07103-2406 (Dr Reichman).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection: A Randomized Trial
Menzies et al.
ANN INTERN MED 2008;149:689-697.
ABSTRACT | FULL TEXT  

Enhancement of Treatment Completion for Latent Tuberculosis Infection With 4 Months of Rifampin
Lardizabal et al.
Chest 2006;130:1712-1717.
ABSTRACT | FULL TEXT  

Considering the Role of Four Months of Rifampin in the Treatment of Latent Tuberculosis Infection
Reichman et al.
Am. J. Respir. Crit. Care Med. 2004;170:832-835.
FULL TEXT  

Treatment Completion and Costs of a Randomized Trial of Rifampin for 4 Months versus Isoniazid for 9 Months
Menzies et al.
Am. J. Respir. Crit. Care Med. 2004;170:445-449.
ABSTRACT | FULL TEXT  

Tuberculosis Prevention in Methadone Maintenance Clinics . Effectiveness and Cost-Effectiveness
SNYDER et al.
Am. J. Respir. Crit. Care Med. 1999;160:178-185.
ABSTRACT | FULL TEXT  

Preventive Therapy for Tuberculosis in HIV-Infected Persons: Analysis of Policy Options Based on Tuberculin Status and CD4+Cell Count
Sawert et al.
Arch Intern Med 1998;158:2112-2121.
ABSTRACT | FULL TEXT  

Skin Anergy Testing and Tuberculosis Surveillance
Lincoln et al.
J Correct Health Care 1997;4:139-153.
ABSTRACT  

Effect of Isoniazid Chemoprophylaxis on HIV-Related Mycobacterial Disease
Graham et al.
Arch Intern Med 1996;156:889-894.
ABSTRACT  

Tuberculosis, AIDS, and Death among Substance Abusers on Welfare in New York City
Friedman et al.
NEJM 1996;334:828-833.
ABSTRACT | FULL TEXT  

Health-Care Expenditures for Tuberculosis in the United States
Brown et al.
Arch Intern Med 1995;155:1595-1600.
ABSTRACT  

Mycobacterium tuberculosis Infection in Pregnant and Nonpregnant Women Infected With HIV in the Women and Infants Transmission Study
Mofenson et al.
Arch Intern Med 1995;155:1066-1072.
ABSTRACT  

High Risk of Active Tuberculosis in HIV-Infected Drug Users With Cutaneous Anergy
Selwyn et al.
JAMA 1992;268:504-509.
ABSTRACT  

Prevalence of Tuberculin Positivity and Skin Test Anergy in HIV-1--Seropositive and --Seronegative Intravenous Drug Users
Graham et al.
JAMA 1992;267:369-373.
ABSTRACT  

Tuberculin Skin Testing and the HIV Epidemic
Huebner et al.
JAMA 1992;267:409-410.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.